Chromosomal Microarray (MicroarrayDx)
New York
Approved
Conditions
- Chromosomal Abnormalities
- Uniparental Disomy
Clinical Utility
- Confirmation of a clinical diagnosis
- Differentiation between de novo and familial cases
- Improved recurrence risk and prognosis
Lab Method
- Whole Genome Chromosomal Microarray
Based on current published guidelines, exome or genome sequencing can now be considered as first-tier tests for patients with unexplained epilepsy, developmental delay, intellectual disabilities and/or congenital anomalies.
To see if you have patients that qualify for a GeneDx Partnership Program, see here.
References:
- Genetics in Medicine (2021) 23:2029–2037; https://doi.org/10.1038/s41436-021-01242-6
- Smith, L., Malinowski, J., Ceulemans, S., Peck, K., Walton, N., Sheidley, B. R., & Lippa, N. (2023). Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. Journal of Genetic Counseling, 32, 266– 280. https://doi.org/10.1002/jgc4.1646
Test Code
910
CPT Codes*
81229x1
ABN Required
No
Turnaround Time**
3 weeks
Preferred Specimen
Alternative Specimen
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.
Test Documents
Billing
For Providers
Targeted Variant Testing